Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
CBRX > SEC Filings for CBRX > Form 8-K on 6-Feb-2014All Recent SEC Filings

Show all filings for COLUMBIA LABORATORIES INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for COLUMBIA LABORATORIES INC


6-Feb-2014

Entry into a Material Definitive Agreement, Financial Statements and Ex


Item 1.01 Entry into a Material Definitive Agreement.

On February 5, 2014, Columbia Laboratories (Bermuda) Ltd. ("Columbia Bermuda"), a wholly owned subsidiary of Columbia Laboratories, Inc., entered into an amendment (the "Amendment") to the Manufacture and Supply Agreement, dated as of December 8, 2009, by and between Columbia Bermuda and Fleet Laboratories Limited (as amended, the "Agreement"), pursuant to which Fleet has agreed to manufacture and supply to Columbia Bermuda, and Columbia Bermuda has agreed to purchase, certain products. The Amendment is effective as of December 31, 2013.

The Amendment extends the term of the Agreement and provides for an expiration date of December 31, 2020 (the "Initial Term"); provided, however, that the Initial Term will be automatically extended for additional periods of two years (each a "Renewal Term") unless either party to the Agreement gives to the other party, not less than six months prior to the expiration of the Initial Term or any Renewal Term, written notice of its intention not to extend the Agreement; and provided further, that upon termination of the Agreement, Fleet agrees to perform its obligations under the Agreement for the earlier of one year or Columbia Bermuda's engagement and qualification of an alternative manufacturer of the Product.

The Amendment also provides that, commencing as of the effective date of the Amendment, and until such time as Columbia Bermuda provides Fleet with notice as described in the Amendment, Fleet will not be obligated to comply with U.S. Food and Drug Administration (FDA) regulatory standards and obligations, in general, unless otherwise specifically required by applicable law; provided, however, that compliance with all other applicable regulatory standards including those of the Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency will remain in effect throughout the period of tolling of the FDA obligations.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

No.     Description

10.1    Amendment to Manufacturing and Supply Agreement, effective as of December
        31, 2013, by and between Columbia Laboratories (Bermuda) Ltd., and Fleet
        Laboratories Limited.


  Add CBRX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for CBRX - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.